A first-of-its-kind AI solution to quantify coronary inflammation and characterise plaque based on routine Coronary Computed Tomography Angiography (CCTA). CaRi-Heart analysis generates an individualised risk score to aid diagnosis and management of coronary artery disease.
Our AI-enabled CaRi-Heart Technology deploys 20+ years of ground-breaking research, scientific publications, and clinical trials.
Current clinical pathways can incorrectly classify patients as low risk by missing inflammatory disease activity and relying on plaque assessment alone. In fact, in terms of absolute numbers, twice as many fatal cardiac events occurred in patients with no obstructive disease on CCTA.*
CaRi-Heart has the potential to transform CCTA from a test to triage a minority of patients for further intervention into a prevention tool that guides management for all patients undergoing CCTA.
*(Lancet 2024, https://doi.org/10.1016/S0140-6736(24)00596-8)
Validated and proprietary biomarker of coronary inflammation
Quantification of inflammation
The CaRi-Heart® platform is a cloud-based Software as a Serivce (SaaS) medical device, providing:
Watch the video to learn how we conduct the CaRi-Heart analysis, to provide a comprehensive risk report.
CaRi-Heart technology can generate results very quickly. Clinicians can receive a Cari-Heart Report after our human verification, which is typically within 48 hours of original order.
CaRi-Heart analysis is only offered through hospitals and healthcare professionals, and the cost may vary in different geographies. For details, hospitals and clinics can write to info@caristo.com.
CaRi-Heart is available in the UK, Europe, and Australia for clinical use.
We require that the hospital or healthcare professional send us a de-identified CCTA scan, for us to conduct a CaRi-Heart analysis.
